Department of Bioengineering, University of Illinois at Urbana-Champaign, 1270 Digital Computer Laboratory, 1304 W. Springfield Ave., Urbana, Illinois 61801, USA.
Lab Chip. 2018 May 15;18(10):1461-1470. doi: 10.1039/c8lc00033f.
Sepsis, an adverse auto-immune response to an infection often causing life-threatening complications, results in the highest mortality and treatment cost of any illness in US hospitals. Several immune biomarker levels, including Interleukin 6 (IL-6), have shown a high correlation to the onset and progression of sepsis. Currently, no technology diagnoses and stratifies sepsis progression using biomarker levels. This paper reports a microfluidic biochip platform to detect proteins in undiluted human plasma samples. The device uses a differential enumeration platform that integrates Coulter counting principles, antigen specific capture chambers, and micro size bead based immunodetection to quantify cytokines. This microfluidic biochip was validated as a potential point of care technology by quantifying IL-6 from plasma samples (n = 29) with good correlation (R2 = 0.81) and agreement (Bland-Altman) compared to controls. In combination with previous applications, this point of care platform can potentially detect cell and protein biomarkers simultaneously for sepsis stratification.
脓毒症是一种对感染的不良自身免疫反应，常导致危及生命的并发症，其在美 国医院的死亡率和治疗费用最高。几种免疫生物标志物水平，包括白细胞介素 6 (IL-6)，与脓毒症的发生和进展有很高的相关性。目前，没有使用生物标志物水平来诊断和分层脓毒症进展的技术。本文报道了一种微流控生物芯片平台，用于检测未经稀释的人血浆样本中的蛋白质。该设备使用一种差分计数平台，该平台集成了库尔特计数原理、抗原特异性捕获室和基于微球的免疫检测，以定量细胞因子。通过对 29 份血浆样本中的 IL-6 进行定量，该微流控生物芯片被验证为一种潜在的即时检测技术，与对照相比具有良好的相关性 (R2 = 0.81) 和一致性 (Bland-Altman)。结合以前的应用，该即时检测平台可潜在地同时检测细胞和蛋白质生物标志物，用于脓毒症分层。
